Press coverage about Alliqua BioMedical (NASDAQ:ALQA) has been trending somewhat positive this week, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alliqua BioMedical earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news articles about the company an impact score of 47.0471082367178 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- DBV Technologies SA (DBVT) is at $44.70 per share and Alliqua BioMedical, Inc. (ALQA) is listed at $0.26 - Stocks Gallery (stocksgallery.com)
- Can This Stock Gain Any Traction: Alliqua BioMedical, Inc. (NASDAQ:ALQA)? - FLBC News (flbcnews.com)
- Alliqua BioMedical, Inc. (ALQA) traded 2305697 shares with change of 14.00% (iphonefresh.com)
- Hot Stock of the Day – Alliqua BioMedical, Inc. (NASDAQ:ALQA) - Stock Watch (stocksnewstimes.com)
- Alliqua BioMedical Inc (ALQA) Awesome Oscillator Trending Lower - Evergreen Caller (evergreencaller.com)
Shares of Alliqua BioMedical (NASDAQ:ALQA) traded down 7.5088% on Friday, reaching $0.2636. 567,860 shares of the company were exchanged. The stock’s market capitalization is $13.21 million. The firm’s 50 day moving average price is $0.34 and its 200 day moving average price is $0.43. Alliqua BioMedical has a 52 week low of $0.23 and a 52 week high of $1.04.
Alliqua BioMedical (NASDAQ:ALQA) last announced its earnings results on Thursday, August 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.05. The business had revenue of $5.52 million for the quarter, compared to analyst estimates of $5.01 million. Alliqua BioMedical had a negative net margin of 185.30% and a negative return on equity of 107.24%. The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.22) earnings per share. Equities research analysts anticipate that Alliqua BioMedical will post ($0.44) EPS for the current year.
A number of research analysts recently weighed in on ALQA shares. HC Wainwright set a $2.00 price objective on shares of Alliqua BioMedical and gave the company a “buy” rating in a research report on Thursday, May 11th. ValuEngine downgraded shares of Alliqua BioMedical from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research upgraded shares of Alliqua BioMedical from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research report on Tuesday, August 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Alliqua BioMedical presently has an average rating of “Hold” and a consensus price target of $1.31.
Alliqua BioMedical Company Profile
Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.
Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
